Back to Trades
Other4
Y-mAbs Therapeutics, Inc.
YMAB
Total Value
$21.1M
Company Information
- Company Name
- Y-mAbs Therapeutics, Inc.
- Ticker Symbol
- YMAB
- CIK
- 0001722964
Insider Information
- Name
- HEALY JAMES
- Role
- Insider
- Location
- MENLO PARK, CA
Filing Details
- Filing Date
- Sep 18, 2025
- Transaction Date
- Sep 16, 2025
- Accession Number
- 0001245624-25-000004
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| — | Common Stock | 31,603 | $8.60 | To Issuer | $271.8K |
| — | Common Stock | 25,080 | — | Disposition | — |
| — | Common Stock | 2,194,278 | $8.60 | To Issuer | $18.9M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| — | Derivative | 14,222 | $11.16 | Disposition | $158.7K |
| — | Derivative | 8,000 | $21.45 | Disposition | $171.6K |
| — | Derivative | 11,000 | $48.67 | Disposition | $535.4K |
| — | Derivative | 11,000 | $37.53 | Disposition | $412.8K |
| — | Derivative | 16,000 | $16.64 | Disposition | $266.2K |
| — | Derivative | 13,950 | $8.13 | Disposition | $113.4K |
| — | Derivative | 14,545 | $12.01 | Disposition | $174.7K |
| — | Derivative | 33,450 | $4.51 | Disposition | $150.9K |
Footnotes
- (F1)Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
- (F2)Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration.
- (F3)Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.
- (F4)At the Effective Time, pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the Merger Consideration.
- (F5)The Reporting Person is one of the managing members of the general partner of Sofinnova Management X-A, L.L.C., the general partner of Sofinnova Management X, L.P., the general partner of Sofinnova Venture Partners X, L.P., which directly holds the reported securities, and, as such, may be deemed to share voting and investment power over such shares. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners X, L.P.
- (F6)At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.